Powerful Medical Wins MedTech Innovator 2025
Powerful Medical has been named MedTech Innovator 2025, winning MTI’s Mid-Stage Grand Finals—top honor from the world’s largest medtech accelerator. The award recognizes PMcardio and its FDA Breakthrough-designated Queen of Hearts™ AI ECG technology, which doubles sensitivity for detecting severe heart attacks and significantly cuts ECG-to-balloon time in large clinical trials.
New York, Nov 24, 2025 – Powerful Medical today announced that it has won MedTech Innovator’s (MTI) 2025 Mid-Stage Grand Finals, earning the prestigious title of “MedTech Innovator 2025.” This award is the top honor from the world’s largest life-science accelerator.
As a finalist, Powerful Medical competed at the MedTech Strategist Innovation Summit, November 19-21, 2025, in San Diego, California. Powerful Medical presented PMcardio with its FDA Breakthrough-designated Queen of Hearts™ AI ECG technology that enables early and accurate detection of severe heart attacks — particularly STEMI and STEMI equivalents — across pre-hospital, point-of-care, and emergency care environments.
“Winning MedTech Innovator’s 2025 Mid-Stage Grand Finals competition is an extraordinary achievement,” said Martin Herman, Co-Founder & CEO of Powerful Medical. “This recognition validates our mission to transform acute cardiac care. With PMcardio and the Queen of Hearts AI, clinicians can diagnose life-threatening heart attacks with twice the sensitivity of the current standard of care — and do so at first medical contact, when every minute determines how much of the heart can still be saved.”
Powerful Medical just recently made headlines with its late-breaking clinical science data presented at TCT 2025, demonstrating that using the Queen of Hearts STEMI AI ECG model to analyze electrocardiograms (ECGs) significantly improves detection of severe heart attacks while reducing false-positive cath lab activations five fold.
Further strengthening these findings, the largest RCT of AI in cardiology—the multicenter DIFOCCULT-3 randomized controlled trial with 6,000 ACS patients—demonstrated that integrating Queen of Hearts AI into clinical workflows resulted in nearly a 5-hour decrease in ECG-to-balloon time. This marks a significant improvement in the timeliness of definitive treatment.
Together, these landmark results position Powerful Medical to reshape first-medical-contact diagnosis and the global standard of care for severe heart attacks.
In the 2025 MTI cohort, selected from nearly 1,500 global applicants, Powerful Medical took home the title of MedTech Innovator 2025 and won the Mid-Stage Grand Finals.
About PMcardio and Powerful Medical
PMcardio is a diagnostic and care coordination platform developed by Powerful Medical, a medical device manufacturer specializing in AI-driven cardiovascular diagnostics. Clinically validated to detect 49 cardiac conditions from an ECG, it identifies acute heart attacks up to three hours earlier and with twice the sensitivity of the current standard of care. This enables timely and accurate triage in emergency settings. By reducing treatment delays and door-to-balloon times, PMcardio facilitates optimized care for chest pain patients. Already class IIb CE-marked under EU MDR in Europe, and pending FDA approval, it enhances acute cardiac care by supporting faster, more confident clinical decisions.
About MedTech Innovator
MedTech Innovator is the world’s largest accelerator of medical device, digital health, and diagnostic companies. Its mission is to improve human health by accelerating the growth of companies transforming patient care. MTI has been a catalyst for groundbreaking healthcare solutions, sourcing nearly 14,000 applicants and fostering the growth of over 800 graduates. Alumni have collectively raised $10+ billion in follow-on funding and introduced 500+ products to the market, improving the health of millions worldwide. In 2025, MTI selected 64 companies from nearly 1,500 global applicants for its highly competitive accelerator cohort, representing the top 4% of innovations worldwide. Companies benefit from MTI’s comprehensive program of mentorship, strategic guidance, and access to an unparalleled network of medtech strategics, investors, providers, and payers. For more information about MedTech Innovator, its annual programs, portfolio of industry-leading startups, and insights on trends, visit MTI’s website, follow them on LinkedIn, and subscribe to its monthly newsletter.
Media Kit and Press Resources
For journalists, partners, and conference organizers — access official press materials, study visuals, company background, and leadership bios in the Powerful Medical Media Kit.linkedin.com/company/powerful-medical
Share this article
About PMcardio
PMcardio is a CE-marked Class IIb AI medical device that interprets any 12-lead ECG — from a photo or a digital file — in seconds. It detects 50+ ECG findings, including occlusion myocardial infarction (OMI) — the acute coronary occlusions that conventional STEMI criteria miss in over half of cases. Its Queen of Hearts™ OMI model holds FDA Breakthrough Device Designation, and PMcardio is already used by 100,000+ clinicians who have analyzed more than 2.5 million ECGs.
About Powerful Medical
Powerful Medical is a medical-technology company using artificial intelligence to transform how cardiovascular disease — the world’s leading cause of death — is diagnosed. Founded in 2017, it built PMcardio, the world’s first AI medical device to detect acute coronary occlusion (OMI) from an ECG. Its research is published in the European Heart Journal – Digital Health and validated across 25+ clinical studies, and its Queen of Hearts™ model earned FDA Breakthrough Device Designation. To date, PMcardio has supported the detection of 120,000+ heart attacks across 150+ hospital deployments worldwide.
